ClinicalTrials.gg
RecruitingNCT07225803Updated Nov 10, 2025

Management of Dyssynergic Defecation

An interventional study of Biofeedback and Inspiratory muscle training (IMT) in Dyssynergic Defecation and Constipation, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Constipation by Mayo Clinic — 4 open to participants now, 5 under way, none of them phase 3. Constipation · Mayo Clinic.

Planned enrollment
Largest of 11
200 · median 52
Started
2025
with 1 other
No phase
5 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Constipation by Mayo Clinic, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 14th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

4 of the 14 studies in Constipation by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Constipation by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to better understand constipation and improve biofeedback treatments.

03

Conditions studied

  • Dyssynergic Defecation
  • Constipation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18-80 years who are able and willing to provide written and to comply with the requirements for the entire study
  • Satisfy Rome III criteria for functional constipation and/or irritable bowel syndrome as assessed by questionnaires and objective evidence of dyssynergic defecation on anorectal testing

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other diseases that may interfere with the objectives of the study and/or pose safety concerns.
  • History of total, hemi- or subtotal colectomy at any time or other abdominal operations within 60 days prior to entry into the study. Segmental resection of the colon (e.g. sigmoid resection) for diverticulitis will be permitted.
  • Current anal fissure
  • structural abnormalities (eg, rectocele > 4cm, large enterocele, full thickness rectal prolapse) that, in the opinion of the investigator, are likely contributing to symptoms
  • Current or past history of colon or rectal cancer, scleroderma, inflammatory bowel disease, congenital anorectal abnormalities, solitary rectal ulcer syndrome, rectal resection or pelvic irradiation
  • Pregnant or nursing women, prisoners and institutionalized individuals
  • >35 kg/m2
  • Use of opioid analgesics or GLP-1 receptor agonists. Patients on opioids will be allowed to participate if they have discontinued them for at least 1 week before the date of screening and are willing to stay off them for the duration of the study.
  • Current use of anticholinergics (eg. amitriptyline, hyoscyamine). Patients who use low dose tricyclic antidepressants (nortriptyline or amitriptyline up to 50 mg/day) will be eligible provided they do not increase the dose during the study period. Patients on higher doses are eligible to participate if it is safe and they are willing to reduce their medication dose at least 3 days (72 hrs) before the date of screening and are willing to stay off them till the study is complete.
  • Current use of laxatives (Ex-lax, senna, herbal supplements), linaclotide, lubiprostone, and prucalopride to treat constipation- patients using these medications will be eligible to participate if they can discontinue the medication at least 3 days (72 hrs.) before the date of screening and are willing to stay off them till the study is complete (As detailed later, all participants can use Miralax throughout the study).
  • Any other factors that increase the risk to participants of participating in the study and/or undermine the integrity of the data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Biofeedback and inspiratory muscle training (BFT Plus)

    Subjects in the BFT Plus arm will participate in a minimum of 6 up to a maximum of 20 biofeedback sessions, with each session lasting approximately 60 minutes. In addition, subjects will engage in inspiratory muscle training (IMT) at home.

    Behavioral: Biofeedback · Behavioral: Inspiratory muscle training (IMT)

  • Active comparator
    Biofeedback only (BFT Alone)

    Subjects in the BFT Plus arm will participate in a minimum of 6 up to a maximum of 20 biofeedback sessions, with each session lasting approximately 60 minutes.

    Behavioral: Biofeedback

Interventions

  • BehavioralBiofeedback

    During anorectal biofeedback therapy, subjects are coached to improve abnormal patterns while observing activity recorded by manometry and/or surface EMG (electromyography) on a computer monitor while seated on a chair or a commode.

  • BehavioralInspiratory muscle training (IMT)

    Subjects will engage in inspiratory muscle training (IMT) that is tailored to the baseline performance of the individual.

06

What researchers measure

Primary outcomes

  1. Change in rectoanal gradient during evacuation

    Rectoanal gradient during evacuation is the pressure difference between the rectum and the anal canal during simulated evacuation, measured in millimeters of mercury (mmHg).

    Time frame: Baseline, through study completion, an average of 16 weeks

  2. Change in rectal pressure during evacuation

    Rectal pressure during evacuation is the difference in rectal pressure during - before evacuation. Results are measured in millimeters of mercury (mmHg).

    Time frame: Baseline, through study completion, an average of 16 weeks

  3. Change in balloon expulsion time

    Rectal balloon expulsion directly assesses evacuation. Patients will be asked to expel a rectal balloon inflated up to 50 ml of water. The time required to expel the balloon will be measured and reported in seconds.

    Time frame: Baseline, through study completion, an average of 16 weeks

  4. Change in rectal emptying time

    Rectal emptying will be assessed via fecoflowmetry by measuring the time required to defecate (seconds) artificial stool from the rectum

    Time frame: Baseline, through study completion, an average of 16 weeks

  5. Change in rectal emptying rate

    Rectal emptying will be assessed via fecoflowmetry by measuring the amount (gm) of artificial stool from the rectum. The 2 metrics - amount and time - are integrated to measure amount (gm) evacuated per unit time (second) (gm/sec).

    Time frame: Baseline, through study completion, an average of 16 weeks

Secondary outcomes

  1. Change in Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire

    The PAC-SYM questionnaire assesses the severity of patient-reported symptoms related to constipation. The questionnaire is divided into three symptom subscales: abdominal (four items); rectal (three items); and stool (five items). Items are scored on 5-point Likert scales, with scores ranging from 0 to 4 (0 = 'symptom absent', 1 = 'mild', 2 = 'moderate', 3 = 'severe' and 4 = 'very severe'). A mean total score in the range of 0-4 is generated by dividing the total score by the number of questions completed; the lower the total score, the lower the symptom burden. Scores range from 0 to 48.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  2. Change in Patient Assessment of Constipation - Quality of Life (PAC-QOL) questionnaire

    The PAC-QOL questionnaire is a patient-reported outcome measure to evaluate quality of life in constipated persons. The questionnaire is divided into four subscales: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items). Scale scores represent average item scores and range from 0 to 4, where higher scores represent poorer quality of life. Scores range from 0 to 112.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion , 12 months post completion

  3. Physical Activity Rating Scale

    Physical Activity Rating is a questionnaire for categorizing physical activity level, which is used in the equation for the non-exercise fitness test. The Physical Activity Rating is a score value between 0 to 7. The non-exercise fitness test of VO2max, a measure of cardiovascular fitness, will be calculated using the following equation: 56.363 + 1.921 (Physical Activity Rating) - 0.381(Age) - 0.754(Body Mass Index) + 10.987(Sex: 0 for women, 1 for men)

    Time frame: Baseline

  4. Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire

    Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) 11-item questionnaire is a standardized tool to measure the satisfaction of an individual who is using an assistive device. It inquiries about the assistive device itself: dimensions, weight, ease of adjustment, safety, durability, ease of use, comfortability, and effectiveness; and service: service delivery, maintenance, professional services, and follow up services. Each question is answered on a Likert scale, where 1 = not satisfied at all, and 5 = very satisfied. Possible scores range from 11 to 55.

    Time frame: through study completion, an average of 16 weeks

  5. Change in stool frequency

    Daily number of bowel movements will be self-reported by participants via a bowel diary.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  6. Change in stool consistency

    Daily stool consistency will be self-reported by participants via a bowel diary by using the Bristol Stool Chart. Participants will compare stool's appearance to the 7 types and selecting the one that most closely matches. Type 1-2 indicate constipation, Type 3-4 are ideal stools as they are easier to pass, and Type 5-7 may indicate diarrhea and urgency.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  7. Change in anal digitation

    The total number of times anal digitation was required to achieve a bowel movement will be self-reported via the bowel diary.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  8. Change in sense of incomplete evacuation

    The total number of times a participant felt a sense of incomplete evacuation after a bowel movement will be self-reported via the bowel diary.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  9. Change in spontaneous bowel movements

    The total number of times a participant achieves a spontaneous bowel movement will be self-reported via the bowel diary.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  10. Change in pain during bowel movements

    Pain during bowel movements will be self-reported by participants via the bowel diary using a 4-point Likert scale (0 = None, 1 = Mild, 3 = Moderate, and 4 = Severe).

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  11. Change in bowel symptoms before and after biofeedback therapy

    Bowel symptoms pre and post biofeedback therapy will be assessed using a self-reported questionnaire. The survey includes Severity of constipation, satisfaction with bowel movements, satisfaction with current treatment of constipation, severity of constipation compared to baseline, adequate relief of constipation, use of laxatives, and severity of abdominal bloating and distention. Impact of constipation on 15 QOL domains.

    Time frame: Baseline, through study completion, an average of 16 weeks, 3 months post completion, 12 months post completion

  12. Change in Hospital Anxiety and Depression (HAD) score

    The Hospital Anxiety and Depression (HAD) is a self-reported 14 item questionnaire asking participants to reflect on their mood in the past week. . Each item is rated on a 4-point scale, for a total score ranging from 0-21 for each subscale. A higher score indicates higher distress.

    Time frame: Baseline, through study completion, an average of 16 weeks

  13. Change in forced vital capacity

    Forced vital capacity (FVC) is the the total volume of air exhaled with maximal effort, and is measured using a spirometer (reported in liters).

    Time frame: Baseline, through study completion, an average of 16 weeks

  14. Change in forced expiratory volume

    Forced expiratory volume (FEV) is the total volume of air exhaled with maximal effort, and is measured using a spirometer (reported in liters).

    Time frame: Baseline, through study completion, an average of 16 weeks

  15. Change in forced expiratory time

    Forced expiratory time (FET) is the time taken to exhale the greatest volume of air from the lungs as possible and is measured using a spirometer (reported in seconds).

    Time frame: Baseline, through study completion, an average of 16 weeks

  16. Change in peak inspiratory flows

    Peak inspiratory flow (PIF) is the maximum volume and rate of air that can be forcefully inhaled out of the lungs, and is measured using a spirometer (reported in liters per second (L/sec)).

    Time frame: Baseline, through study completion, an average of 16 weeks

  17. Change in peak expiratory flows

    Peak expiratory flow (PEF) is the maximum volume and rate of air that can be forcefully exhaled out of the lungs and is measured using a spirometer (reported in in liters per second (L/sec)).

    Time frame: Baseline, through study completion, an average of 16 weeks

  18. Change in forced expiratory volume/forced vital capacity ratio

    The total volume of air exhaled with maximal effort / The volume of air exhaled with maximum effort in the first second (reported as percentage).

    Time frame: Baseline, through study completion, an average of 16 weeks

  19. Change in forced expiratory flow at 25-75% of forced vital capacity

    The average flow from the point at which 25% of the forced vital capacity has been exhaled to the point at which 75% of the forced vital capacity has been exhaled. A reduced forced expiratory flow 25-75% is a marker of small airway obstruction.

    Time frame: Baseline, through study completion, an average of 16 weeks

  20. Change in forced expiratory flow at 50% of forced vital capacity

    The flow rate at the point at which 50% point of the forced vital capacity has been exhaled, and is a marker of small airway obstruction.

    Time frame: Baseline, through study completion, an average of 16 weeks

  21. Change in forced inspiratory vital capacity

    Forced inspiratory vital capacity is the maximum volume of air that can be inhaled after a full expiration (reported in liters).

    Time frame: Baseline, through study completion, an average of 16 weeks

  22. Change in peak inspiratory pressure

    Peak inspiratory pressure is the peak pressure during forceful inspiration against an occluded airway (Mueller maneuver), reported in liters per minute (L/min)

    Time frame: Baseline, through study completion, an average of 16 weeks

  23. Change in peak expiratory pressure

    Peak expiratory pressure is the peak pressure during forceful expiration against an occluded airway (Valsalva maneuver), reported in liters per minute (L/min)

    Time frame: Baseline, through study completion, an average of 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 36 months is above that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Nov 10, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225803
Lead sponsor
Mayo Clinic
Responsible party
Adil Bharucha, MBBS, MD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 10, 2025
Start date
Jul 18, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 10, 2025

Study contacts

Kelly J. Feuerhak, RN, CCRP
Contact
feuerhak.kelly@mayo.edu
507-255-6802
Adil E. Bharucha, MBBS, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion